141.65 USD
-3.65 (-2.51%)
141.9 USD
+0.25 (+0.18%)
Overall ILMN gets a fundamental rating of 5 out of 10. We evaluated ILMN against 57 industry peers in the Life Sciences Tools & Services industry. While ILMN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ILMN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- ILMN had positive earnings in the past year.
- ILMN had a positive operating cash flow in the past year.
- In multiple years ILMN reported negative net income over the last 5 years.
- In the past 5 years ILMN always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 11.38%, ILMN belongs to the best of the industry, outperforming 91.23% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 29.53%, ILMN belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
- ILMN has a better Return On Invested Capital (16.40%) than 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 16.39%, ILMN belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
- The Operating Margin of ILMN (20.41%) is better than 85.96% of its industry peers.
- In the last couple of years the Operating Margin of ILMN has declined.
- Looking at the Gross Margin, with a value of 66.74%, ILMN belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
- ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ILMN is creating some value.
- ILMN has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for ILMN has been increased compared to 5 years ago.
- ILMN has a worse debt/assets ratio than last year.
2.2 Solvency
- ILMN has an Altman-Z score of 4.67. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
- ILMN's Altman-Z score of 4.67 is fine compared to the rest of the industry. ILMN outperforms 75.44% of its industry peers.
- The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
- ILMN's Debt to FCF ratio of 1.99 is amongst the best of the industry. ILMN outperforms 87.72% of its industry peers.
- ILMN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
- ILMN's Debt to Equity ratio of 0.42 is in line compared to the rest of the industry. ILMN outperforms 40.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.67 |
ROIC/WACC1.51
WACC10.88%
2.3 Liquidity
- A Current Ratio of 1.43 indicates that ILMN should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.43, ILMN is doing worse than 77.19% of the companies in the same industry.
- ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of ILMN (1.12) is worse than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.02%, which is quite impressive.
- Measured over the past years, ILMN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -17.93% on average per year.
- ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -2.32%.
- Measured over the past years, ILMN shows a small growth in Revenue. The Revenue has been growing by 4.29% on average per year.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
- The Earnings Per Share is expected to grow by 24.95% on average over the next years. This is a very strong growth
- Based on estimates for the next years, ILMN will show a small growth in Revenue. The Revenue will grow by 3.99% on average per year.
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.99%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 32.49, ILMN can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, ILMN is valued a bit cheaper than the industry average as 68.42% of the companies are valued more expensively.
- ILMN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 27.64 indicates a quite expensive valuation of ILMN.
- Based on the Price/Forward Earnings ratio, ILMN is valued a bit cheaper than the industry average as 71.93% of the companies are valued more expensively.
- ILMN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.49 | ||
| Fwd PE | 27.64 |
4.2 Price Multiples
- ILMN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 78.95% of the companies in the same industry.
- ILMN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ILMN is cheaper than 87.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.64 | ||
| EV/EBITDA | 19.73 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ILMN has a very decent profitability rating, which may justify a higher PE ratio.
- ILMN's earnings are expected to grow with 34.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y34.05%
5. Dividend
5.1 Amount
- ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
141.65
-3.65 (-2.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners104.7%
Inst Owner Change0.59%
Ins Owners0.17%
Ins Owner Change-0.21%
Market Cap21.64B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts73.33
Price Target132.25 (-6.64%)
Short Float %4.86%
Short Ratio4.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)2.26%
PT rev (3m)10.92%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)3.08%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.49 | ||
| Fwd PE | 27.64 | ||
| P/S | 5.05 | ||
| P/FCF | 21.64 | ||
| P/OCF | 19.29 | ||
| P/B | 9.09 | ||
| P/tB | 20.75 | ||
| EV/EBITDA | 19.73 |
EPS(TTM)4.36
EY3.08%
EPS(NY)5.13
Fwd EY3.62%
FCF(TTM)6.54
FCFY4.62%
OCF(TTM)7.34
OCFY5.18%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.34
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.67 |
F-Score7
WACC10.88%
ROIC/WACC1.51
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.99%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year36.79%
EBIT Next 3Y17.14%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
Can you provide the valuation status for ILLUMINA INC?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
What is the financial health of ILLUMINA INC (ILMN) stock?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
What is the expected EPS growth for ILLUMINA INC (ILMN) stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.03% in the next year.